AIkido Pharma Inc. (AIKI): Price and Financial Metrics
GET POWR RATINGS... FREE!
AIKI Stock Price Chart Interactive Chart >
AIKI Price/Volume Stats
| Current price | $3.56 | 52-week high | $11.48 |
| Prev. close | $3.55 | 52-week low | $3.31 |
| Day low | $3.50 | Volume | 31,900 |
| Day high | $3.67 | Avg. volume | 79,326 |
| 50-day MA | $4.72 | Dividend yield | N/A |
| 200-day MA | $5.81 | Market Cap | 19.53M |
AIkido Pharma Inc. (AIKI) Company Bio
Spherix Incorporated, a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. The company's platform consists of patented technology from leading universities and researchers and in the process of developing an innovative therapeutic drug platform through partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. It has a scientific research agreement with The University of Texas Southwestern Medical Center to use machine learning to find genetic markers in people that indicate an increased risk of developing pancreatic cancer. Spherix Incorporated was founded in 1967 and is based in New York, New York.
Latest AIKI News From Around the Web
Below are the latest news stories about AIKIDO PHARMA INC that investors may wish to consider to help them evaluate AIKI as an investment opportunity.
Dominari Holdings Provides Update on Share Repurchase ProgramDominari Holdings Inc. (Nasdaq: DOMH) ("Dominari" or the "Company") today provided an update on the $2 million share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on December 5, 2022. |
AIkido Pharma Announces Name and Stocker Ticker Symbol Change to Dominari Holdings Inc. (Nasdaq: DOMH)AIkido Pharma Inc. (NASDAQ: AIKI) (the "Company") today announced that it has changed its name from AIkido Pharma Inc. to Dominari Holdings Inc. and its ticker symbol from "AIKI" to "DOMH." The Company expects that its shares of common stock will begin trading on The Nasdaq Stock Market under the new name and new stock ticker symbol "DOMH" on or about December 22, 2022. |
AIkido Pharma Announces Successful Initial Public Offering of ASP IsotopesAIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company") today announced the successful initial public offering ("IPO") of ASP Isotopes ("ASPI"). ASPI priced its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share, for aggregate gross proceeds of approximately $5.0 million before deducting underwriting discounts, commissions, and other offering expenses. |
AIkido Pharma (AIKI) Gets a Buy from H.C. WainwrightIn a report released today, Vernon Bernardino from H.C. Wainwright maintained a Buy rating on AIkido Pharma (AIKI - Research Report), with a price target of $16.00. The company's shares opened today at $4.30.Bernardino covers the Healthcare sector, focusing on stocks such as Geron, Artelo Biosciences, and Cassava Sciences. According to TipRanks, Bernardino has an average return of 19.4% and a 32.49% success rate on recommended stocks. AIkido Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $16.00.See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $13.90 and a one-year low of $4.14. |
AIkido Share Repurchase ContinuesAIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022. |
AIKI Price Returns
| 1-mo | N/A |
| 3-mo | -35.27% |
| 6-mo | -39.35% |
| 1-year | -57.03% |
| 3-year | -79.47% |
| 5-year | -96.30% |
| YTD | N/A |
| 2022 | 0.00% |
| 2021 | -32.80% |
| 2020 | -33.83% |
| 2019 | -51.47% |
| 2018 | -54.29% |
Loading social stream, please wait...